FDA Inspection 1252166 — Hangzhou Solipharma Co., Ltd.
The FDA completed an inspection of Hangzhou Solipharma Co., Ltd. on Sep 20, 2024 in Hangzhou. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Sep 20, 2024
- Fiscal Year
- 2024
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Hangzhou (China)